Navigation Links
AACR in Medical Technology

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

Pivotal Trial Expected to Initiate in 2010 for Blinatumomab NEW YORK, April 24 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today held an R&am...

Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model

-Preclinical Results Further Validate Significant Anti-Tumor Potential of Fully Human Anti-PS Antibodies and Expand the Company's PS-Targeting Platform- -Treatment with Mouse Equivalent to the Human Antibody Inhibited Tumor Growth in a Prostate Cancer Model by More than 90%- DE...

Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies

- Preclinical Studies Highlight the Ability of PS-Targeting Antibodies to Reverse the Immune Suppressing Effects of Tumors by Changing the Tumor Microenvironment and Mobilizing Key Components of the Immune System - - Studies Confirm Peregrine's PS-Targeting Antibodies Stimulate Dendritic C...

Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting

SAN DIEGO, April 17 /PRNewswire/ -- Cylene Pharmaceuticals announced today that it will be presenting new data on recent advances of its small molecule anticancer agents during a symposium and several poster presentations at the American Association for Cancer Research (AACR) annual meeting, to be...

EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting

Compounds Demonstrate Potent Antitumor Activity in a Variety of Tumor Types ROCKVILLE, Md., April 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced t...

Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors

SAN DIEGO and SUNNYVALE, Calif., April 15 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced preclinical data from four presentations at the Annual Meeting of the American Association for Cancer Research (AACR) being held this week in San Diego, CA. Results from mul...

Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab

- Bavituximab Causes Pro-Inflammatory Effects in the Tumor Microenvironment That May Contribute to Its Anti-Tumor Efficacy - - Studies Show Similar Results for a New Fully Human Version of the Antibody - SAN DIEGO and TUSTIN, Calif., April 15 /PRNewswire...

Preclinical Study Presented at AACR Annual Meeting Shows Peregrine's Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model

- 80% of Subjects Immunized with Anti-PS Immunocytokines and Irradiated Tumor Cells Achieved Long-Term Survival Compared to Just 20% of Controls - - Data Highlights Broad Anti-Cancer Potential of Peregrine's Anti-PS Vascular Targeting Antibodies - SAN DIEGO and TUSTIN, Cal...

Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer

-No Metastatic Lesions Were Detectable After Combination Therapy Treatment- -Survival Time More Than Doubled in Animals Treated with Combination Therapy- -Established Tumors Regressed by 50% After Combination Therapy Treatment- SAN DIEGO and TUSTIN, Calif., April...

Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies

-Combination of a Bavituximab Equivalent and an Agent that Re-Activates the Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical Breast Cancer Models- SAN DIEGO and TUSTIN, Calif., April 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (...

Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting

SAN FRANCISCO, April 14 /PRNewswire-FirstCall/ -- Positive preclinical data was presented by Nektar Therapeutics (Nasdaq: NKTR ) this week for its lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which demonstrated enhanced anti-tumor activity in a mouse xenograft model of colorectal canc...

PG500 Series Presented at the AACR Annual Meeting in San Diego

BRISBANE, Australia, April 14 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL) (Nasdaq: PGLA ) announced today that it had presented new data on its patented PG500 series of compounds at the annual American Association for Cancer Research (AACR) meeting being held in San Di...

EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting

Oral Presentation During the "New Drugs on the Horizon 2" Special Session ROCKVILLE, Md., April 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced it...

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting

DUBLIN, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been a...

Specialized Genasense(R) Clinical Trials Featured at AACR Meeting

BERKELEY HEIGHTS, N.J., April 7, 2008 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA ) announced that presentations related to Genasense(R) (oblimersen sodium) Injection, the Company's lead anticancer compound will be featured at the annual meeting of the American Association for ...

SuperGen's Novel Hypomethylating Agent Highlighted at AACR Plenary Session

S110 preclinical data presented by Dr. Peter Jones, Director of USC's Norris Cancer Center SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of th...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

HAYWARD, Calif., April 16 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) presented preclinical data on its proprietary nuclear export inhibitors (NEI) showing potent in vitro and in vivo activity as well as tolerability in leukemia xenograft models, and further eluci...

Oncolytics Biotech Inc. Collaborators to Present Reovirus/Gemcitabine Combination Research at AACR Annual Meeting

CALGARY, March 13, 2007 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. announced today that an abstract covering preclinical work using reovirus in combination with gemcitabine is available today on the American Association for Cancer Research (AACR) website at

Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting

Four Posters Relating to Company Oncology Programs to be Presented SOUTH SAN FRANCISCO, Calif., April 09, 2007 /PRNewswire-FirstCall/ -- Cytokinetics, Incorporated announced today that four posters containing non-clinical data will be presented at the 2007 Annual Meeting of the American Associatio...

Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

HAYWARD, Calif., April 10, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated announced data will be presented on the Company's clinical and preclinical pipeline, including its Hsp90 inhibitor, epothilone and nuclear export inhibitor programs, at the 2007 Annual Meeting of the American ...

CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting

BRANFORD, Conn., April 12, 2007 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of ...

Enzon to Present Preclinical Data From PEG-SN38 and PEGylation Technology Studies at AACR Meeting

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Apr 12, 2007 - Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that four posters containing preclinical data will be presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) to be held from April 14 - 18, 2007 in Los ...

Ascenta Therapeutics Highlights Multiple Data Presentations at Upcoming AACR Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Apr 13, 2007 - Ascenta Therapeutics, Inc. announced today that its small molecule portfolio of apoptosis-triggering compounds will be featured in three oral presentations and several poster presentations at next week's 2007 Annual Meeting of the American Association for ...

AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles

QUEBEC CITY, April 13, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two abstracts outlining first in vitro data on its PI3K inhibitors as well as in vivo data on i...

CombinatoRx to Present Combination High Throughput Screening (cHTS) Data at Upcoming AACR Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that posters related to its oncology research efforts will be presented at the 98th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007 in Los Angeles, CA. "Sys...

AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles

Second generation pyridopyrazine-urea derivative compound series show highly selective PI3K-inhibition which could be valuable for cancer treatment QUEBEC, April 16, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and...

Rigel to Present New Research Programs at AACR Meeting

Focus on Rigel's Extensive Oncology Portfolio SOUTH SAN FRANCISCO, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced the presentation of four research projects aimed at identifying small molecule inhibitors of select kinases as potential therapeutics for ...

Poster on Cyclosert Drug Delivery Presented at AACR Meeting

Novel System May Provide Cancer Patients With Improved Potential to Battle Their Disease PASADENA, Calif., April 16, 2007 /PRNewswire/ -- Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation announced today its novel delivery system called Cyclosert(TM) will be ...

Novelos Therapeutics and MUSC Present Two Posters at AACR 2007 Annual Meeting

NEWTON, Mass.--(BUSINESS WIRE)--Apr 16, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the company, in collaboration with Dr. Kenneth Tew and Dr. Danyelle Townsend of the Med...

Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models

- Peregrine's Selective Anti-VEGF Antibodies Inhibited Tumor Growth By 90% In a Preclinical Cancer Model - - Peregrine's Antibodies that Selectively Inhibit VEGF Receptor 2 Could Potentially Have Advantages over Non-Selective Approaches - - These Results Along wit...

Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting

Novel Systems May Provide Cancer Patients With Improved Potential to Battle Their Disease PASADENA, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Arrowhead Research Corporation announced today that two of its majority-owned subsidiaries, Insert Therapeutics Inc. and Calando Pharmaceuticals Inc....

Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting

Data Indicate Significant Anti-Tumor Effects of Targeted, Systemic siRNA Therapeutic at Doses Significantly Lower Than the Limits of Safe Administrations in Rodent and Non-Human Primates PASADENA, Calif., April 16, 2007 /PRNewswire/ -- Calando Pharmaceuticals, a leading siRNA therapeutics company ...

Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 16, 2007 - Amgen (Nasdaq:AMGN) today presented the results from a randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of Aranesp(R) (darbepoetin alfa) for the treatment of anemia in patients with active cancer not...

AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles

JMR-132 could provide a new therapeutic approach for the treatment of early and metastatic breast cancer QUEBEC CITY, April 17, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today presented an abstract...

GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy

GAITHERSBURG, Md.--(BUSINESS WIRE)--Apr 17, 2007 - GenVec, Inc. (Nasdaq:GNVC) announced today data from two studies presented at the 97th annual meeting of the American Association of Cancer Research (AACR) that further support the use of adenovector systems to deliver the gene for tumor necrosis f...

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies

- Combination Therapy Significantly Decreased Tumor Blood Vessel Density and Serum PSA Levels in Prostate Tumors - LOS ANGELES and TUSTIN, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing targeted monoclonal an...

terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles

Second generation pyridopyrazine-urea derivative compound series show highly selective PI3K-inhibition which could be valuable for cancer treatment QUBEC CITY, Canada, April 16, 2007 terna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global, pure play biopharmaceutical company foc...

Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting

MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Apr 18, 2007 - Gemin X today announced the presentation of positive preclinical data from a study of its lead compound, GX15-070 (obatoclax), in infant acute lymphoblastic leukemia (ALL). The study was discussed in an oral presentation at the Annual Mee...
Other Tags
(Date:8/20/2014)... honeybees grows to about 4,000 members, it triggers an ... of a special type of comb used for rearing ... the Department of Neurobiology and Behaviour at Cornell University, ... cycle of honeybee colonies. The results are published in ... . , Reproduction isn,t always a honeybee colony,s ...
(Date:8/19/2014)... decrease China,s increasing caesarean section rate, suggests a new ... International Journal of Obstetrics and Gynaecology (BJOG) . , ... in the world. Of 16 million babies born in ... rate is not known, the current Chinese language literature ... ranging from 36% to 58%. However, before the 1980s, ...
(Date:8/19/2014)... It,s not a monkey. It,s not a lemur. It,s ... Meet the Philippine tarsier: a tiny, adorable and downright "cool" ... animals that Americans are familiar with," said Rafe Brown, curator-in-charge ... giant eyes and ears; an extremely cute, furry body; a ... interesting expanded fingers and toe tips that look a bit ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
(Date:8/21/2014)... (PRWEB) August 21, 2014 Taking its ... all aspects of life, St. Louis’ Sound Mind Café ... better and revolutionized its online presence. Reorganized to highlight ... the new website makes navigating for information and scheduling ... an easily accessible menu-bar in jet black, the cafe’s ...
(Date:8/21/2014)... 2014 According to a recent study ... environmental factors may outweigh genetics in the development and severity ... the world’s population is nearsighted, and this study provides valuable ... is an important finding in the field of ophthalmology,” says ... we finding better ways to treat ophthalmological conditions , ...
(Date:8/21/2014)... While golfing in Scotland and abroad, Biteback ... focused on his game due to the incessant buzzing ... and continual need to spray insect repellent became so ... from insects while golfing. He ultimately found a solution ... Banking Industry, decided to change direction and launch Biteback ...
(Date:8/21/2014)... Denver marketing agency Webolutions® has ... Lung Association in Colorado’s 2014 Run the ‘Rocks ... a sponsor,” said Curt Huber, Chief Development Officer, American ... Lung Association in Colorado, “and we’re eager to see ... they’ve defined.” , Webolutions has also created and is ...
(Date:8/21/2014)... August 21, 2014 HIPAA Secure Now! ... making it possible for EHR vendors to now offer ... requirement for achieving meaningful use. , HIPAA Secure ... to medical practices throughout the U.S. The company assesses ... information (ePHI) from each system and device used by ...
Breaking Medicine News(10 mins):Health News:Sound Mind Cafe Launches Revamped Website and Hires Hypnotist to Team 2Health News:Study Suggests Environmental Factors May Outweigh Genetics When It Comes to Myopia 2Health News:Financial VP Fights Pesky Bugs with Launch of Biteback Sports Insect Shield® Golf Apparel 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 3Health News:HIPAA Secure Now! Ramps up EHR Partner Program, Helps Healthcare Providers Achieve Meaningful Use under Revised CMS Deadlines 2
Other Contents